Evidence analysisOctober 21, 2026Evidence
Agenda – HMA / EMA multistakeholder AI and Data forum: Build trustworthy AI on strong data foundations

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.
What is established
The agenda for the HMA (Heads of Medicines Agencies) and EMA (European Medicines Agency) multistakeholder AI and Data forum, scheduled for 2026, outlines a collaborative event focusing on building trustworthy artificial intelligence (AI) solutions based on robust data foundations. The forum represents a coordinated initiative among European regulatory agencies and stakeholders to address the integration of AI and data science in the pharmaceutical and healthcare regulations.
What the source claims
The draft event agenda published by the EMA describes a comprehensive forum that aims to bring together multiple stakeholders—including regulators, industry participants, and data experts—to discuss frameworks, challenges, and strategies for reliable AI in healthcare. It emphasizes the importance of strong data governance, quality, transparency, and collaboration to ensure AI technologies can be trusted and effectively regulated.
- The forum agenda covers sessions on AI transparency, data quality standards, ethical considerations, and regulatory readiness.
- There is a clear focus on fostering multistakeholder dialogue to align perspectives on AI development and regulation.
- The event aims to explore data infrastructures and methodologies that contribute to trustworthy AI models in medicinal product regulation.
- Connecting AI system developers with regulatory bodies is positioned as a central goal to improve understanding and compliance.
What may be missing from the usual framing
The agenda document is primarily procedural and promotional, thus it does not explicitly address the potential challenges, limitations, or controversies inherent in deploying AI for regulatory purposes. For instance, discussions around power asymmetries between large tech companies and public agencies, risks of data biases, or the potential impact on patient privacy and autonomy are not substantively covered in the publicly available agenda.
There is also little direct mention of independent oversight mechanisms or public participation beyond “multistakeholder” consultation, which can sometimes be limited to established industry and institutional actors. Consideration of how marginalized voices or divergent viewpoints will be included is not explicitly detailed.
Competing evidence or uncertainty
Evidence is insufficient to determine how effectively the forum’s commitments will translate into concrete regulatory reforms or enforceable standards around trustworthy AI. While the event agenda signals intent and priorities, actual regulatory outcomes will depend on subsequent policy development, political will, technological advances, and stakeholder engagement.
There is uncertainty about the specific criteria and benchmarks that will be used to assess “trustworthiness” of AI within medicine regulation. The complexity of AI systems and evolving data practices pose challenges that are not fully addressable in forum discussions alone.
In addition, no detailed information is provided regarding independent audits, transparency in decision-making by regulators using AI tools, or accountability frameworks to manage AI-related risks.
Why it matters
As AI technologies increasingly influence healthcare decisions, diagnostics, and regulatory oversight, establishing trustworthy AI is critical for patient safety, public health, and scientific integrity. Regulatory agencies like EMA play a crucial role in safeguarding these values while enabling innovation.
This forum indicates a proactive approach by European regulators to align multiple stakeholders and build consensus around AI standards. Successful collaboration can lay a foundation for responsible AI deployment in medicine and potentially serve as a model internationally.
However, without transparency about governance, power dynamics, and safeguards against systemic biases or errors, there is a risk that AI implementation could reinforce existing inequities or introduce new risks.
What to verify next
- Follow up on post-forum reports or publications to assess outcomes, agreements, and any regulatory shifts resulting from the event.
- Examine how patient advocacy groups and independent researchers are engaged to ensure diverse viewpoints in AI governance.
- Investigate specific regulatory guidelines or frameworks issued by EMA or HMA that operationalize concepts of trustworthy AI.
- Monitor transparency and accountability measures adopted by regulatory agencies as AI systems become integrated into decision-making processes.
Readers interested in the full context should refer directly to the original draft agenda document issued by EMA for detailed session topics and objectives.
Source & verification
Primary source: What's new · October 21, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: A target trial emulation
Loss to follow-up during tuberculosis treatment and 5-year mortality in Brazil: evidence dossier What is established Tuberculosis (TB) remains a leading cause of infectious…

Disagreement doesn’t have to be toxic
Evidence Dossier: The Nature and Practice of Disagreement What is established Disagreement is a common and unavoidable part of social life, extending beyond politics…

Business professor? Perhaps more ‘detective of human behavior.’
Lauren Cohen: Investigating the Social Dynamics Behind Financial Markets This evidence dossier explores insights from an interview and profile published by the Harvard Gazette…